Indivior Pharmaceuticals, Inc. (INDV)

Every figure this model derived for INDV, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 71,000,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 222,000,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 725,000,000 AssetsCurrent 2026-06-30
current liabilities 868,000,000 LiabilitiesCurrent 2026-06-30
equity -208,000,000 StockholdersEquity 2026-06-30
interest expense 27,000,000 InterestExpenseNonoperating 2026-06-30
ocf -40,000,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 1,332,000,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 32,000,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up INDV on one particular measure came for.

RatioValue
cash operating margin34.68
current ratio0.84
current ratio reported0.84
dilution pct-3.76
ebit yoy92.24
fcf margin-8.33
growth cv0.53
interest cover15.59
net debt ebitda0.62
operating margin31.61
owner earnings margin-10.74
revenue growth13.46
revenue growth per share17.89
roic583.49
rule of 4045.06
sbc pct revenue2.4

What to be careful about

What this model itself distrusts about INDV's figures. Written by the derivation as it ran, not added afterwards.